The current peak in COVID-19 cases has resulted in a significant increase in demand on NHS services. This has been further compounded by the general winter pressures and increased workload for both primary and secondary care with the increased incidence of flu and respiratory illnesses as well as the reduced staffing levels due to illness [...]
As a result of the Covid 19 pandemic, many menopause services have changed their service provision to either telephone or video consultations where appropriate in order to offer alternatives to face to face appointments thereby helping to minimise patients’ hospital visits. The British Menopause Society (BMS) would like to find out more about your experience [...]
As a result of the Covid 19 pandemic, many menopause services have changed their service provision to either telephone or video consultations where appropriate in order to offer alternatives to face to face appointments thereby helping to minimise patients’ hospital visits. The British Menopause Society (BMS) would like to find out more about your views [...]
Exciting news from the British Menopause Society. Launched today on World Menopause Day: a significant, new education programme for healthcare professionals – Principles and Practices of Menopause Care (PPMC).
Cagnacci,a,* G. Bonaccorsi,b M. Gambacciani,c and the board of the Italian Menopause Society have provided advice on the use of hormone therapy during the Covid 19 pandemic. On reviewing available evidence, they have concluded that while a recommendation for COVID-19-positive individuals to stop hormone therapy or oral contraceptives may seem wise, it is not based on real data. [...]
The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and clinical practitioners in response to the ongoing HRT shortages. The British Menopause Society has issued this further update on the current availability of HRT products to provide guidance to BMS members and [...]
This is an updated Joint BMS, IMS, EMAS, RCOG and AMS Position Statement on HRT and breast cancer risk and includes a summary of the evidence on dydrogesterone. We are aware that the statement is likely to be used by healthcare professionals to guide clinical practice and we believe this additional information would be of [...]
A joint statement has been issued by the British Menopause Society, the International Menopause Society, the European Menopause and Andropause Society, the Royal College of Obstetricians and Gynaecologists and the Australasian Menopause Society on menopausal hormone therapy (MHT) and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.
A joint statement has been issued by the British Menopause Society, the Royal College of Obstetricians and Gynaecologists, the Royal College of General Practitioners, the Faculty of Sexual and Reproductive Healthcare, the Faculty of Occupational Medicine and the Faculty of Public Health in response to the BMA report ‘Challenging the culture on menopause for doctors’.
The RCOG and BMS issue a joint statement on the Women’s Health Initiative’s (WHI) study on HRT and breast cancer incidence and mortality.
